within Pharmacolibrary.Drugs.ATC.R;

model R01AD58
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.8333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.318,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R01AD58</td></tr><td>route:</td><td>intranasal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fluticasone is a synthetic corticosteroid used in combination therapy for the treatment of allergic rhinitis and other nasal inflammatory conditions. As an intranasal glucocorticoid, it reduces inflammation, itching, and runny nose associated with allergies. Combinations with other agents, such as antihistamines or decongestants, provide added therapeutic efficacy. Fluticasone nasal preparations are widely approved and in clinical use for both adults and children.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following typical nasal spray administration.</p><h4>References</h4><ol><li><p>Ridolo, E, et al., &amp; Canonica, GW (2015). A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis. <i>Therapeutic delivery</i> 6(6) 653–659. DOI:<a href=&quot;https://doi.org/10.4155/tde.15.7&quot;>10.4155/tde.15.7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25913181/&quot;>https://pubmed.ncbi.nlm.nih.gov/25913181</a></p></li><li><p>Allen, A, et al., &amp; Miller, SR (2016). Pharmacokinetics, Safety, and Tolerability of Once-Daily Intranasal Fluticasone Furoate and Levocabastine Administered Alone or Simultaneously as fluticasone Furoate/Levocabastine Fixed-Dose Combination. <i>Clinical pharmacology in drug development</i> 5(3) 225–231. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.218&quot;>10.1002/cpdd.218</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27163502/&quot;>https://pubmed.ncbi.nlm.nih.gov/27163502</a></p></li><li><p>Wolthers, OD (2013). New patents of fixed combinations of nasal antihistamines and corticosteroids in allergic rhinitis. <i>Recent patents on inflammation &amp; allergy drug discovery</i> 7(3) 223–228. DOI:<a href=&quot;https://doi.org/10.2174/1872213x113079990019&quot;>10.2174/1872213x113079990019</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23862774/&quot;>https://pubmed.ncbi.nlm.nih.gov/23862774</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R01AD58;
